Dyadic International, Inc.
Every calculator, already run for DYAI
Open the full toolkit →You have the numbers on DYAI. Get the argument.
A written report on which of these readings actually decide the outcome for Dyadic International, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
1 analysts covering DYAIOwnership & short interest
About Dyadic International, Inc.
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vacc…
DYAI — frequently asked
Is DYAI a buy right now?
Wall Street's consensus rating on Dyadic International, Inc. is none across 1 analysts, with a mean price target of $6.00 (+511% vs. the current $0.98). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is DYAI's next earnings date?
Dyadic International, Inc. is next scheduled to report earnings around Aug 12, 2026. A full DYAI research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
Compare Dyadic International, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Dyadic International, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full DYAI research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Dyadic International, Inc., in minutes. 3 free reports included with every account — no credit card required.